Please login to the form below

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene takes PD-1 antibody into pivotal trials

The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five approved drugs have been launched in the big Chinese ... There is a huge pent-up need for new cancer immunotherapies. However, while the

Latest news

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo has said it thinks that the drug will increase the activity of PD-1/PD-L1 checkpoint inhibitors. ... Lilly already has a PD-L1 drug in phase I testing, while Armo also has a PD-1 antibody heading for clinical trials as well as recombinant IL-12 and
BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also not go ahead. ... 1/PD-L1 inhibitors, but the drug has been firmly relegated to speculative status.
Merck’s Keytruda scores in frontline lung cancer yet again

NSCLC, including those with both squamous and non-squamous types and a full range of PD-L1 expression levels from 1% and above. ... are both hoping to find a role for combinations pairing PD-1/PD-L1 inhibitors with CTLA4 inhibitors.
Incyte/Merck trial failure bodes ill for IDO class

BMS is also partnered with Incyte on a trial of its PD-1 inhibitor Opdivo (nivolumab) with epacadostat, as is AstraZeneca with its PD-L1 blocker Imfinzi (durvalumab), so the blow ... That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined
AZ pushes back data read-out from MYSTIC lung cancer trial

questions about the validity of combining PD-1/PD-L1 and CTLA4 inhibitors in these patients. ... TMB differs from the usual PD-L1 expression biomarker used in trials of PD-1/PD-L1 inhibitors and has been proposed as a superior option for immuno-oncology

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response, ”says Xuan.
European venture funding for the life science sector

is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
Medius Deal Watch table for March 2015

170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
Deal Watch table for November 2014

PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Associate Medical Director: Salary TBC

Editorial Director – Medical Education: Neg

Account Manager, Healthcare Advertising: Salary TBC

Account Director: Negotiable

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Project / Account Manager (Medical Education): Salary TBC

Scientific Team Lead: Competitive Salary

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Director – Head of Public Affairs: Neg

Account Director - Digital: Great salary and benefits

Experienced Editor, London, Medical Communications: Competitive package

Director Healthcare PR Communications: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director – Global Healthcare PR: Salary TBC

Associate Medical Director: Highly Competitive

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Executive – Medical Communications: Salary TBC

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...